Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Intensive chemotherapy for AML: do we still need it?

Christoph Röllig • 15 Jun 2019
EHA 2019
Acute Myeloid Leukemia

Christoph Röllig, MD, Dresden University of Technology, Dresden, Germany, discusses the treatment options for acute myeloid leukemia (AML), and whether intensive chemotherapy is still clinically relevant. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Christoph Röllig

2:19
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML
Christoph Röllig • 11 Dec 2023
1:45
HAM-Ven as salvage treatment for R/R AML: results from the SAL-RELAX trial
Christoph Röllig • 11 Dec 2023
2:26
Improving long-term outcomes with intensive chemotherapy in AML: looking to the future
Christoph Röllig • 11 Dec 2023
2:05
Results from the Phase I SAL-RELAX trial: venetoclax plus cytarabine and mitoxantrone in R/R AML
Christoph Röllig • 10 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals